Richard A. Heyman is Director at Enliven Therapeutics, Inc. (ELVN). They have made 2 open-market trades across 2 companies since 2021, most recently 2026-07-24.
CIK 0001584759
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ORIC | 206,672 | $2.6M |
| ELVN | 22,647 | $846K |
| PMVP | 558 | $675 |
| RCPT | 7,400 | — |
| YMTX | 8,117 | — |
| Total | $3.4M |
Shares reported on the most recent Form 4, priced at the 2026-07-28 close. 2 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ORIC | SELL · 10b5-1 | 2026-07-24 | 2026-07-28 | $12.02 | $157K | +14.5% | +16.7% | — |
| ORIC | SELL · 10b5-1 | 2026-07-06 | 2026-07-08 | $12.00 | $4K | -4.5% | +23.7% | +9.8% |
| ELVN | SELL · 10b5-1 | 2026-02-17 | 2026-02-19 | $26.18 | $32K | +10.8% | +18.8% | +61.5% |
| ELVN | SELL · 10b5-1 | 2026-01-20 | 2026-01-22 | $26.75 | $33K | +2.3% | +1.7% | +64.7% |
| ORIC | SELL · 10b5-1 | 2026-01-16 | 2026-01-20 | $12.00 | $80K | -10.9% | -1.6% | -5.6% |
| ELVN | SELL | 2026-01-08 | 2026-01-12 | $25.02 | $348K | +3.1% | +12.0% | +75.3% |
| ELVN | SELL · 10b5-1 | 2024-10-18 | 2024-10-22 | $30.00 | $47K | -3.8% | -11.6% | -23.4% |
| ELVN | SELL · 10b5-1 | 2024-10-15 | 2024-10-17 | $27.67 | $35K | +1.3% | -11.5% | -19.5% |
| ELVN | SELL · 10b5-1 | 2024-10-04 | 2024-10-08 | $27.51 | $155K | +4.1% | +4.1% | -13.6% |
| ELVN | SELL · 10b5-1 | 2024-10-01 | 2024-10-03 | $27.54 | $14K | +6.5% | +5.9% | -8.5% |
| ELVN | SELL · 10b5-1 | 2024-09-16 | 2024-09-18 | $22.41 | $28K | +13.2% | +28.5% | +8.1% |
| ELVN | SELL · 10b5-1 | 2024-08-15 | 2024-08-19 | $23.25 | $30K | -5.4% | -7.3% | +6.0% |
| ELVN | SELL · 10b5-1 | 2024-07-31 | 2024-08-02 | $27.51 | $65K | +3.6% | +5.5% | +32.3% |
| ELVN | SELL · 10b5-1 | 2024-07-15 | 2024-07-17 | $24.80 | $31K | +12.3% | +0.2% | +17.6% |
| ELVN | SELL · 10b5-1 | 2024-06-17 | 2024-06-20 | $21.48 | $27K | +3.4% | +11.4% | +3.7% |
| ELVN | SELL · 10b5-1 | 2024-05-16 | 2024-05-20 | $23.74 | $30K | -6.0% | -12.3% | -2.0% |
| ELVN | SELL · 10b5-1 | 2024-04-11 | 2024-04-15 | $24.49 | $294K | -14.3% | +22.6% | +28.2% |
| ELVN | SELL · 10b5-1 | 2024-03-19 | 2024-03-21 | $14.50 | $18K | +3.1% | -2.3% | +16.7% |
| ELVN | SELL · 10b5-1 | 2024-02-15 | 2024-02-20 | $17.42 | $22K | +2.1% | +10.7% | +47.1% |
| ELVN | SELL · 10b5-1 | 2024-01-30 | 2024-02-01 | $16.41 | $21K | -7.0% | +4.4% | +13.4% |
| ELVN | SELL · 10b5-1 | 2023-12-21 | 2023-12-26 | $13.00 | $3K | -9.8% | +12.9% | +22.9% |
| ELVN | SELL · 10b5-1 | 2023-12-19 | 2023-12-21 | $13.02 | $56K | +12.5% | +13.6% | +48.1% |
| ORIC | SELL · 10b5-1 | 2021-09-14 | 2021-09-16 | $25.04 | $35K | -12.8% | -41.3% | -50.4% |
| ORIC | SELL · 10b5-1 | 2021-09-10 | 2021-09-14 | $25.05 | $27K | -5.0% | -34.4% | -48.9% |
| ORIC | SELL · 10b5-1 | 2021-09-07 | 2021-09-09 | $25.11 | $27K | +0.8% | -35.8% | -36.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.